{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:14:23Z","timestamp":1771661663141,"version":"3.50.1"},"reference-count":35,"publisher":"Walter de Gruyter GmbH","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_dmpt-2020-0127_abs_001_w2aab3b7c57b1b6b1aab1c14b2Aa\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>For revealing the peculiarities of the drug\u2013drug interaction of rivaroxaban (substrate CYP3A4 and P-gp) and calcium channel blockers (CCBs) (verapamil\u00a0\u2013 inhibitor CYP3A4 and P-gp and amlodipine\u00a0\u2013 substrate CYP3A4) in patients 80 years and older with nonvalvular atrial fibrillation (NAF) we studied 128 patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_dmpt-2020-0127_abs_002_w2aab3b7c57b1b6b1aab1c14b3Aa\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>All patients were divided into groups depending on the therapy taken: the 1st\u00a0\u2013 rivaroxaban\u00a0+ amlodipine (n=51), the 2nd\u00a0\u2013 rivaroxaban\u00a0+ verapamil (n=30), the control group\u00a0\u2013 rivaroxaban without CCBs (n=47). A trough steady-state plasma concentration (<jats:italic>C<\/jats:italic>\n                     <jats:sub>min,ss<\/jats:sub>) of rivaroxaban, prothrombin time (PT) in the blood plasma and the event of clinically relevant non-major (CRNM) bleeding were assessed for each patient.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_dmpt-2020-0127_abs_003_w2aab3b7c57b1b6b1aab1c14b4Aa\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Patient in group 2 had higher <jats:italic>C<\/jats:italic>\n                     <jats:sub>min,ss<\/jats:sub> of rivaroxaban, PT and CRNM than subjects in the control group (Me 73.8 [50.6\u2013108.8] ng\/mL vs. 40.5 [25.6\u201374.3] ng\/mL; Me 14.8 [13.4\u201317.3] s vs. 13.8 [12.6\u201314.4] s; 34% vs. 13%, respectively, p&lt;0.05 for all). When compared, the PT and complication rate in group 1 with the control group <jats:italic>C<\/jats:italic>\n                     <jats:sub>min,ss<\/jats:sub> of rivaroxaban were practically the same (p&gt;0.05 for all).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_dmpt-2020-0127_abs_004_w2aab3b7c57b1b6b1aab1c14b5Aa\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In patients\u00a0\u226580 years with NAF, the use of rivaroxaban in combination with verapamil may not be safe and can lead to CRNM bleeding.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/dmpt-2020-0127","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T13:58:34Z","timestamp":1657893514000},"source":"Crossref","is-referenced-by-count":11,"title":["Drug\u2013drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation"],"prefix":"10.1515","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4496-3680","authenticated-orcid":false,"given":"Dmitry","family":"Sychev","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology and Therapy of Federal State Budgetary Educational Institution of Further Professional Education \u201cRussian Medical Academy of Continuous Professional Education\u201d of the Ministry of Healthcare of the Russian Federation , Moscow , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9307-4994","authenticated-orcid":false,"given":"Karin","family":"Mirzaev","sequence":"additional","affiliation":[{"name":"Department of Personalized Medicine , Research Institute of Molecular and Personalized Medicine of Federal State Budgetary Educational Institution of Further Professional Education \u201cRussian Medical Academy of Continuous Professional Education\u201d of the Ministry of Healthcare of the Russian Federation , Moscow , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3091-7904","authenticated-orcid":false,"given":"Marina","family":"Cherniaeva","sequence":"additional","affiliation":[{"name":"Department of Internal and Preventive Medicine of Federal State Budgetary Institution of Higher Professional Education \u201cCentral State Medical Academy of the Presidential Administration of the Russian Federation\u201d , Marshal Timoshenko street,19, building 1A, 121359 , Moscow , Russia"},{"name":"State Budgetary Institution of Health \u201cHospital for War Veterans No. 2\u201d of the Department of Health of Moscow , Volgogradsky prospect , Moscow , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5107-8834","authenticated-orcid":false,"given":"Maria","family":"Kulikova","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapy of Federal State Budgetary Educational Institution of Further Professional Education \u201cRussian Medical Academy of Continuous Professional Education\u201d of the Ministry of Healthcare of the Russian Federation , Moscow , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8555-5969","authenticated-orcid":false,"given":"Pavel","family":"Bochkov","sequence":"additional","affiliation":[{"name":"Department of Personalized Medicine , Research Institute of Molecular and Personalized Medicine of Federal State Budgetary Educational Institution of Further Professional Education \u201cRussian Medical Academy of Continuous Professional Education\u201d of the Ministry of Healthcare of the Russian Federation , Moscow , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4646-7733","authenticated-orcid":false,"given":"Roman","family":"Shevchenko","sequence":"additional","affiliation":[{"name":"Department of Personalized Medicine , Research Institute of Molecular and Personalized Medicine of Federal State Budgetary Educational Institution of Further Professional Education \u201cRussian Medical Academy of Continuous Professional Education\u201d of the Ministry of Healthcare of the Russian Federation , Moscow , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Gorbatenkova","sequence":"additional","affiliation":[{"name":"State Budgetary Institution of Health \u201cHospital for War Veterans No. 2\u201d of the Department of Health of Moscow , Volgogradsky prospect , Moscow , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8579-7167","authenticated-orcid":false,"given":"Olga","family":"Golovina","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapy of Federal State Budgetary Educational Institution of Further Professional Education \u201cRussian Medical Academy of Continuous Professional Education\u201d of the Ministry of Healthcare of the Russian Federation , Moscow , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0795-8225","authenticated-orcid":false,"given":"Olga","family":"Ostroumova","sequence":"additional","affiliation":[{"name":"Department of Therapy and Polymorbid Pathology of Federal State Budgetary Educational Institution of Further Professional Education \u201cRussian Medical Academy of Continuous Professional Education\u201d of the Ministry of Healthcare of the Russian Federation , Moscow , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4434-9311","authenticated-orcid":false,"given":"Damirya","family":"Bahteeva","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapy of Federal State Budgetary Educational Institution of Further Professional Education \u201cRussian Medical Academy of Continuous Professional Education\u201d of the Ministry of Healthcare of the Russian Federation , Moscow , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2511-0655","authenticated-orcid":false,"given":"Eric","family":"Rytkin","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapy of Federal State Budgetary Educational Institution of Further Professional Education \u201cRussian Medical Academy of Continuous Professional Education\u201d of the Ministry of Healthcare of the Russian Federation , Moscow , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2020,9,4]]},"reference":[{"key":"2022071513563063064_j_dmpt-2020-0127_ref_001_w2aab3b7c57b1b6b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Chugh, SS, Havmoeller, R, Narayanan, K, Singh, D, Rienstra, M, Benjamin, EJ, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation 2014;129:837\u201347. https:\/\/dx.doi.org\/10.1161\/CIRCULATIONAHA.113.00511.","DOI":"10.1161\/CIRCULATIONAHA.113.005119"},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_002_w2aab3b7c57b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Colilla, S, Crow, A, Petkun, W, Singer, DE, Simon, T, Liu, X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 2013;112:1142\u20137. https:\/\/dx.doi.org\/10.1016\/j.amjcard.2013.05.063.","DOI":"10.1016\/j.amjcard.2013.05.063"},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_003_w2aab3b7c57b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Wolf, PA, Abbott, RD, Kannel, WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983\u20138. https:\/\/dx.doi.org\/10.1161\/01.str.22.8.983.","DOI":"10.1161\/01.STR.22.8.983"},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_004_w2aab3b7c57b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Russ J Cardiol 2017;7:7\u201386. http:\/\/dx.doi.org\/10.15829\/1560-4071-2017-7-7-86.","DOI":"10.15829\/1560-4071-2017-7-7-86"},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_005_w2aab3b7c57b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Kishore, A, Vail, A, Majid, A, Dawson, J, Lees, KR, Tyrrell, PJ, et al. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke. 2014;45:520\u20136. https:\/\/dx.doi.org\/10.1161\/STROKEAHA.113.003433.","DOI":"10.1161\/STROKEAHA.113.003433"},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_006_w2aab3b7c57b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Henriksson, KM, Farahmand, B, Asberg, S, Edvardsson, N, Terent, A. Comparison of cardiovascular risk factors and survival in patients with ischemic or hemorrhagic stroke. Int J Stroke 2012;7:276\u201381. https:\/\/dx.doi.org\/10.1111\/j.1747-4949.2011.00706.x.","DOI":"10.1111\/j.1747-4949.2011.00706.x"},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_007_w2aab3b7c57b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Grond, M, Jauss, M, Hamann, G, Stark, E, Veltkamp, R, Nabavi, D, et al. Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. Stroke 2013;44:3357\u201364. https:\/\/dx.doi.org\/10.1161\/STROKEAHA.113.001884.","DOI":"10.1161\/STROKEAHA.113.001884"},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_008_w2aab3b7c57b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Steffel, J, Verhamme, P, Potpara, TS, Albaladejo, P, Antz, M, Desteghe, L, et al. The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace 2018;20:1231\u201342. https:\/\/doi.org\/10.1093\/europace\/euy054.","DOI":"10.5603\/KP.2018.0180"},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_009_w2aab3b7c57b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Ostroumova, OD, Cherniaeva, MS, Golovina, OV. Atrial fibrillation as risk factor for development of cognitive function impairment and dementia. Potential of anticoagulant therapy in their prevention. Kardiologiia 2018;58:76\u201388. https:\/\/doi.org\/10.18087\/cardio.2018.9.10173.","DOI":"10.18087\/cardio.2018.9.10173"},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_010_w2aab3b7c57b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Ostroumova, OD, Kochetkov, AI, Korchagina, SP, Ostroumova, TM, Chernyaeva, MS, Kirichenko, AA. Anticoagulant therapy as a tool for the prevention of cognitive impairment associated with atrial fibrillation. Rational Pharmacother Cardiol 2019;15:713\u201324. https:\/\/doi.org\/10.20996\/1819-6446-2019-15-5-713-724.","DOI":"10.20996\/1819-6446-2019-15-5-713-724"},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_011_w2aab3b7c57b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Outes, A, Terleira-Fern\u00e1ndez, AI, Lecumberri, R, Su\u00e1rez-Gea, ML, Vargas-Castrill\u00f3n, E. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Thromb Res 2014;134:774\u201382. https:\/\/doi.org\/10.1016\/j.thromres.2014.06.020.","DOI":"10.1016\/j.thromres.2014.06.020"},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_012_w2aab3b7c57b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Mani, H, Lindhoff-Last, E. New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy quality of life, and cost effectiveness. Drug Des Dev Ther 2014;8:789\u201398. https:\/\/doi.org\/10.2147\/DDDT.S45644.","DOI":"10.2147\/DDDT.S45644"},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_013_w2aab3b7c57b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Rottenstreich, A, Zacks, N, Kleinstern, G, Raccah, BH, Roth, B, Da\u2019as, N, et al. Direct-acting oral anticoagulant drug level monitoring in clinical patient management. J Thromb Thrombolysis 2018;45:543\u20139. https:\/\/doi.org\/10.1007\/s11239-018-1643-0.","DOI":"10.1007\/s11239-018-1643-0"},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_014_w2aab3b7c57b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Hurst, K, Lee, R, Handa, A. Quick reference guide to the new oral anticoagulants. J Vasc Surg 2016;63:1653\u20137. https:\/\/doi.org\/10.1016\/j.jvs.2016.02.054.","DOI":"10.1016\/j.jvs.2016.02.054"},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_015_w2aab3b7c57b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Samuelson, BT, Cuker, A, Siegal, DM, Crowther, M, Garcia, DA. Laboratory assessment of the anticoagulant activity of direct oral anticoagulants. A systematic review. Chest 2017;151:127\u201338. https:\/\/doi.org\/10.1016\/j.chest.2016.08.1462.","DOI":"10.1016\/j.chest.2016.08.1462"},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_016_w2aab3b7c57b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Wieland, E, Shipkova, M Pharmacokinetic and pharmacodynamic drug monitoring of direct acting oral anticoagulants: where do we stand? Ther Drug Monit 2019;41:180\u201391. https:\/\/doi.org\/10.1097\/FTD.0000000000000594.","DOI":"10.1097\/FTD.0000000000000594"},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_017_w2aab3b7c57b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Mueck, W, Stampfuss, J, Kubitza, D, Becka, M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 2014;53:1\u201316. https:\/\/doi.org\/10.1007\/s40262-013-0100-7.","DOI":"10.1007\/s40262-013-0100-7"},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_018_w2aab3b7c57b1b6b1ab2b1c18Aa","unstructured":"Bayer Pharma, AG Xarelto (rivaroxaban) summary of product characteristics. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000944\/WC500057108.pdf. [Accessed 20 July 2018]."},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_019_w2aab3b7c57b1b6b1ab2b1c19Aa","unstructured":"Tripodi, A, Ageno, W, Ciaccio, M, Legnani, C, Lippi, G, Manotti, C, et al. Position paper on laboratory testing for patients on direct oral anticoagulants. A consensus document from the SISET, FCSA, SIBioC and SIPMeL. Blood Transfus 2018;16:462\u201370. https:\/\/doi.org\/10.2450\/2017.0124-17."},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_020_w2aab3b7c57b1b6b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;39:3021\u2013104. https:\/\/doi.org\/10.1093\/eurheartj\/ehy339.","DOI":"10.1093\/eurheartj\/ehy339"},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_021_w2aab3b7c57b1b6b1ab2b1c21Aa","unstructured":"Kharkevich, DA. Pharmacology. Textbook, 12th ed. Moscow: Geotar media; 2018."},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_022_w2aab3b7c57b1b6b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"Zhu, Y, Wang, F, Li, Q, Zhu, M, Du, A, Tang, W, et al. Amlodipine metabolism in human liver microsomes and roles of CYP3A4\/5 in the dihydropyridine dehydrogenation. Drug Metab Dispos 2014;42:245\u20139. https:\/\/doi.org\/10.1124\/dmd.113.055400. [Epub 2013 Dec 3].","DOI":"10.1124\/dmd.113.055400"},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_023_w2aab3b7c57b1b6b1ab2b1c23Aa","doi-asserted-by":"crossref","unstructured":"Wessler, JD, Grip, LT, Mendell, J, Giugliano, RP. The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol 2013;61:2495\u2013502. https:\/\/doi.org\/10.1016\/j.jacc.2013.02.058. [Epub 2013 Apr 3].","DOI":"10.1016\/j.jacc.2013.02.058"},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_024_w2aab3b7c57b1b6b1ab2b1c24Aa","doi-asserted-by":"crossref","unstructured":"Patel, MR, Mahaffey, KW, Garg, J, Pan, G, Singer, DE, Hacke, W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1009638.","DOI":"10.1056\/NEJMoa1009638"},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_025_w2aab3b7c57b1b6b1ab2b1c25Aa","doi-asserted-by":"crossref","unstructured":"Washam, JB, Hellkamp, AS, Lokhnygina, Y, Piccini, JP, Berkowitz, SD, Nessel, CC, et al. Efficacy and safety of rivaroxaban versus warfarin in patients taking nondihydropyridine calcium channel blockers for atrial fibrillation (from the ROCKET AF Trial). Am J Cardiol 2017;120:588\u201394. https:\/\/doi.org\/10.1016\/j.amjcard.2017.05.026.","DOI":"10.1016\/j.amjcard.2017.05.026"},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_026_w2aab3b7c57b1b6b1ab2b1c26Aa","doi-asserted-by":"crossref","unstructured":"Kim, M, Son, H, Noh, K, Kim, E, Shin, BS, Kang, W. Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of rivaroxaban. Pharmaceutics 2019;11. pii: E133. https:\/\/doi.org\/10.3390\/pharmaceutics11030133.","DOI":"10.3390\/pharmaceutics11030133"},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_027_w2aab3b7c57b1b6b1ab2b1c27Aa","doi-asserted-by":"crossref","unstructured":"Greenblatt, DJ, Patel, M, Harmatz, JS, Nicholson, WT, Rubino, CM, Chow, CR. Impaired rivaroxaban clearance in mild renal insufficiency with verapamil coadministration: potential implications for bleeding risk and dose selection. J Clin Pharmacol 2018;58:533\u201340. https:\/\/doi.org\/10.1002\/jcph.1040. [Epub 2017 Nov 30].","DOI":"10.1002\/jcph.1040"},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_028_w2aab3b7c57b1b6b1ab2b1c28Aa","doi-asserted-by":"crossref","unstructured":"Gelman, A, Bois, F, Jiang, J. Physiological pharmacokinetic analysis using population modeling and informative prior distributions. J Am Stat Assoc 1996;436:1400\u201312. https:\/\/doi.org\/10.1080\/01621459.1996.10476708.","DOI":"10.1080\/01621459.1996.10476708"},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_029_w2aab3b7c57b1b6b1ab2b1c29Aa","doi-asserted-by":"crossref","unstructured":"Ismail, M, Lee, VH, Chow, CR, Rubino, CM. Minimal physiologically based pharmacokinetic and drug-drug-disease interaction model of rivaroxaban and verapamil in healthy and renally impaired subjects. J Clin Pharmacol 2018;58:541\u20138. https:\/\/doi.org\/10.1002\/jcph.1044. [Epub 2017 Dec 14].","DOI":"10.1002\/jcph.1044"},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_030_w2aab3b7c57b1b6b1ab2b1c30Aa","doi-asserted-by":"crossref","unstructured":"Chang, SH, Chou, IJ, Yeh, YH, Chiou, MJ, Wen, MS, Kuo, CT, et al. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. JAMA 2017;318:1250\u20139. https:\/\/doi.org\/10.1001\/jama.2017.13883.","DOI":"10.1001\/jama.2017.13883"},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_031_w2aab3b7c57b1b6b1ab2b1c31Aa","doi-asserted-by":"crossref","unstructured":"Bartlett, JW, Renner, E, Mouland, E, Barnes, GD, Kuo, L, Ha NB clinical safety outcomes in patients with nonvalvular atrial fibrillation on rivaroxaban and diltiazem. Ann Pharmacother 2019;53:21\u20137. https:\/\/doi.org\/10.1177\/1060028018795140. [Epub 2018 Aug 13].","DOI":"10.1177\/1060028018795140"},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_032_w2aab3b7c57b1b6b1ab2b1c32Aa","unstructured":"Tkacheva, ON. General principles of pharmacotherapy in elderly and senile persons: methodical recommendations. Moscow: Prometheus; 2019."},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_033_w2aab3b7c57b1b6b1ab2b1c33Aa","doi-asserted-by":"crossref","unstructured":"Skripka, A, Sychev, D, Bochkov, P, Shevchenko, R, Krupenin, P, Kogay, V, et al. Factors affecting trough plasma dabigatran concentrations in patients with atrial fibrillation and chronic kidney disease. High Blood Press Cardiovasc Prev 2020. https:\/\/doi.org\/10.1007\/s40292-020-00373-2.","DOI":"10.1007\/s40292-020-00373-2"},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_034_w2aab3b7c57b1b6b1ab2b1c34Aa","doi-asserted-by":"crossref","unstructured":"Kaatz, S, Ahmad, D, Spyropoulos, AC, Schulman, S. Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 2015;13:2119\u201326. https:\/\/doi.org\/10.1111\/jth.13140.","DOI":"10.1111\/jth.13140"},{"key":"2022071513563063064_j_dmpt-2020-0127_ref_035_w2aab3b7c57b1b6b1ab2b1c35Aa","doi-asserted-by":"crossref","unstructured":"Schulman, S, Kearon, C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692\u20134. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01204.x.","DOI":"10.1111\/j.1538-7836.2005.01204.x"}],"container-title":["Drug Metabolism and Drug Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/dmpt-2020-0127\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/dmpt-2020-0127\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T14:03:22Z","timestamp":1657893802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/dmpt-2020-0127\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":35,"aliases":["10.1515\/dmdi-2020-0127"],"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,9,1]]},"published-print":{"date-parts":[[2020,9,7]]}},"alternative-id":["10.1515\/dmpt-2020-0127"],"URL":"https:\/\/doi.org\/10.1515\/dmpt-2020-0127","relation":{},"ISSN":["2191-0162","0792-5077"],"issn-type":[{"value":"2191-0162","type":"electronic"},{"value":"0792-5077","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,1]]},"article-number":"20200127"}}